Initial clinical trial of a high-affinity retinoic acid receptor ligand (LGD1550)

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 1731-1735

  Soignet, Steven L ^a,c   Miller, Vincent A ^a   Pfister, David G ^a   Bienvenu, Bryan J ^a   Ho, Raymond ^a   Parker, Barbara A ^b   Amyotte, Shirley A ^b   Cato III, Allen ^b   Warrell Jr , Raymond P ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b LIGAND PHARMACEUTICALS INC   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LGD 1550; LIGAND; RETINOIC ACID RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RESEARCH; CLINICAL TRIAL; DOSE RESPONSE; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; PRIORITY JOURNAL; SKIN TOXICITY;

ADULT; AGED; AREA UNDER CURVE; BINDING, COMPETITIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, UNSATURATED; HUMANS; LIGANDS; MIDDLE AGED; NEOPLASMS; RECEPTORS, RETINOIC ACID; TREATMENT OUTCOME;

EID: 0034084925     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Breitman, T., Selonic, S., and Collins, S. J. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc. Natl. Acad. Sci. USA, 77: 2936-2940, 1980.
2. Sporn, M., and Roberts, A. Role of retinoids in differentiation and carcinogenesis. J. Natl. Cancer Inst., 73: 1381-1387, 1984.
3. Martin, S., Bradley, J., and Cotter, T. G. HL-60 cells induced to differentiate towards neutrophils subsequently die via apoptosis. Clin. Exp. Immunol., 79: 448-453, 1990.
4. Soignet, S., Fleischauer, A., Polyak, T., Heller, G., and Warrell, R. P., Jr. All-trans-retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York Study. Cancer Chemother. Pharmacol., 40 (Suppl.): S25-S29, 1997.
5. Mangelsdorf, D. J. Vitamin A receptors. Nutr. Rev., 52: S32-S44, 1994.
6. de The, H., Chomienne, C., Lanotte, M., Degos, L., and Dejean, A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor-α gene to a novel transcribed locus. Nature (Lond.), 347: 558-561, 1990.
7. Mangelsdorf, D. J., Ong, E. S., Dyck, J. A., and Evans, R. M. Nuclear receptor that identifies a novel retinoic acid response pathway. Nature (Lond.), 345: 224-229, 1990.
8. Keller, H., Dreyer, C., Medin, J., Mahfoudi, A., Ozato, K., and Wahli, W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc. Natl. Acad. Sci. USA, 90: 2160-2164, 1993.
9. Zang, X. K., Hoffman, R., Tran, P. B., Graupner, G., and Pfahl, M. Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors. Nature (Lond.), 355: 441-446, 1992.
10. 3 signalling. Nature (Lond.), 355: 446-449, 1992.
11. Shalinsky, D. R., Sheeter, L. M., Bischoff, E. D., Boehm, M., Nadzan, A. M., and Heyman, R. A. ALRT1550, a potent RAR-selective retinoid, synergistically inhibits growth of UMSCC-22B cells in combination with interferon-α2b or cisplatin in vitro. Proc. Am. Assoc. Cancer Res., 37: 293, 1996.
12. Shalinsky, D. R., Bischoff, E., Lamph, W. W., Zhang, L., M. F., Boehm Davies, P. J., Nadzan, A. M., and Heyman, R. A. A novel retinoic acid receptor-selective retinoid, ALRT1550, has potent antitumor activity against human oral squamous carcinoma xenografts in nude mice. Cancer Res., 57: 162-168, 1997.
13. Lee, J. S., Newman, R. A., Lippman, S. M., Huber, M. H., Minor, T., Raber, M. N., Krakoff, I. H., and Hong, W. K. Phase I evaluation of all-trans retinoic acid in adults with solid tumors. J. Clin. Oncol., 11: 959-966, 1993.
14. Miller, V. A., Rigas, J. R., Benedetti, F. M., Verret, A. L., Tong, W. P., Kris, M. G., Gill, G. M., Loewen, G. R., Truglia, J. A., Ulm, E. H., and Warrell, R. P., Jr. Initial clinical trials of the retinoid receptor pan agonist 9-cis retinoic acid. Clin. Cancer Res., 2: 471-475, 1996.
15. Krust, A., Kastner, P., Petkovich, M., Zelent, A., and Chambon, P. A third human retinoic acid receptor, hRAR-γ. Proc. Natl. Acad. Sci. USA, 86: 5310-5314, 1989.
16. Zelent, A., Krust, A., Petkovich, M., Kastner, P., and Chambon, P. Cloning of murine α and β retinoic acid receptors and a novel receptor γ predominantly expressed in skin. Nature (Lond.), 339: 714-717, 1989.
17. Bershad, S., Rubinstein, A., Paterniti, J. R., Le, N. A., Poliak, S. C., Heller, B., Ginsberg, H. N., Fleischmajer, R., and Brown, W. V. Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N. Engl. J. Med., 16: 981-985, 1985.
18. Rigas, J. R., Miller, V. A., Levine, D. M., Venkatraman, E. S., Gil, G. M., Truglia, J. A., and Warrell, R. P., Jr. Lipoprotein alterations in patients treated with novel retinoids. Proc. Am. Assoc. Cancer Res., 36: 506, 1995.
19. Muindi, J. R., Frankel, F. S., Miller, W. H., Jr., Jakubowski, A., Scheinberg, D. A., Young, C. W., Dmitrovsky, E., and Warrell, R. P., Jr. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoic "resistance" in patients with acute promyelocytic leukemia. Blood, 79: 299-303, 1992.